EUROPEAN COMMISSION
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

Health systems, medical products and innovation
Medical products: quality, safety, innovation

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Notification of serious GMP non-compliance information originating from third country authorities or international organisations

Table of contents:

Title	**Notification of serious GMP non-compliance information originating from third country authorities or international organisations**
Date of adoption	May 2012
Date of entry into force	By end November 2012
Supersedes	Not Applicable
Reason for revision	Not Applicable, new guideline
Notes	Not applicable
Last publication date:	1 August 2024
Document version	1

(LETTERHEAD OF COMPETENT AUTHORITY)

Report No: _ _ _/_ _ _/_ __/_ _

Notification of serious GMP non-compliance information originating from third country authorities or international organisations[1]

Exchange of information between National Competent Authorities (NCAs) of the EEA following notification of serious GMP non-compliance at a manufacturer

Part 1

Issued by the competent authority of ……*[Member State]* following notification from a third country authority or international organisation in accordance with reference to CoUP here.

……..*[third country authority / International organisation name]* reports the following:

The manufacturer……..

Site address……
……

DUNS Number (if known)……

Site contact name, title, email, phone and fax number ……

Third country authority / international organisation contact name, title, email, phone and fax number
……

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on …../……/ *[date]*, or from verified information it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in the principles and guidelines of Good Manufacturing Practice laid down in……*[third country / international GMP standards or regulations used for assessment]* , relating to medicinal products/ active substances/ excipients*

[1] To be filled in following the 'Procedure for Dealing with Serious GMP Non-Compliance Information Originating from Third Country Authorities or International Organisations'

Part 2

☐ Human Medicinal Products*
☐ Veterinary Medicinal Products*
☐ Human Investigational Medicinal Products*

• **NON-COMPLIANT MANUFACTURING OPERATIONS – MEDICINAL PRODUCTS***	
1.1	**Sterile Products**
	1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.1 Large volume liquids 1.1.1.2 Lyophilisates 1.1.1.3 Semi-solids 1.1.1.4 Small volume liquids 1.1.1.5 Solids and implants 1.1.1.6 Other <free text>
	1.1.2 Terminally sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.1.2.2 Semi-solids 1.1.2.3 Small volume liquids 1.1.2.4 Solids and implants 1.1.2.5 Other <free text>
	1.1.3 Batch certification
1.2	**Non-sterile products**
	1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.1 Capsules, hard shell 1.2.1.2 Capsules, soft shell 1.2.1.3 Chewing gums 1.2.1.4 Impregnated matrices 1.2.1.5 Liquids for external use 1.2.1.6 Liquids for internal use 1.2.1.7 Medicinal gases 1.2.1.8 Other solid dosage forms 1.2.1.9 Pressurised preparations 1.2.1.10 Radionuclide generators 1.2.1.11 Semi-solids 1.2.1.12 Suppositories 1.2.1.13 Tablets 1.2.1.14 Transdermal patches 1.2.1.15 Intraruminal devices 1.2.1.16 Veterinary premixes 1.2.1.17 Other <free text>
	1.2.2 Batch certification
1.3	**Biological medicinal products**

	1.3.1 Biological medicinal products 1.3.1.1 Blood products 1.3.1.2 Immunological products 1.3.1.3 Cell therapy products 1.3.1.4 Gene therapy products 1.3.1.5 Biotechnology products 1.3.1.6 Human or animal extracted products 1.3.1.7 Tissue engineered products 1.3.1.8 Other <free text >
	1.3.2 Batch certification (list of product types) 1.3.2.1 Blood products 1.3.2.2 Immunological products 1.3.2.3 Cell therapy products 1.3.2.4 Gene therapy products 1.3.2.5 Biotechnology products 1.3.2.6 Human or animal extracted products 1.3.2.7 Tissue engineered products 1.3.2.8 Other <free text >
1.4	**Other products or manufacturing activity**
	1.4.1 Manufacture of: 1.4.1.1 Herbal products 1.4.1.2 Homoeopathic products 1.4.1.4 Other <free text >
	1.4.2 Sterilisation of active substances/excipients/finished product: 1.4.2.1 Filtration 1.4.2.2 Dry heat 1.4.2.3 Moist heat 1.4.2.4 Chemical 1.4.2.5 Gamma irradiation 1.4.2.6 Electron beam
	1.4.3 Others <free text>
1.5	**Packaging**
	1.5.1 Primary packaging 1.5.1.1 Capsules, hard shell 1.5.1.2 Capsules, soft shell 1.5.1.3 Chewing gums 1.5.1.4 Impregnated matrices 1.5.1.5 Liquids for external use 1.5.1.6 Liquids for internal use 1.5.1.7 Medicinal gases 1.5.1.8 Other solid dosage forms 1.5.1.9 Pressurised preparations 1.5.1.10 Radionuclide generators 1.5.1.11 Semi-solids 1.5.1.12 Suppositories 1.5.1.13 Tablets 1.5.1.14 Transdermal patches 1.5.1.15 Intraruminal devices 1.5.1.16 Veterinary premixes 1.5.1.17 Other <free text >
	1.5.2 Secondary packaging

1.6	**Quality control testing**
	1.6.1 Microbiological: sterility
	1.6.2 Microbiological: non-sterility
	1.6.3 Chemical/Physical
	1.6.4 Biological

-
- **NON-COMPLIANT IMPORTATION OPERATIONS***

2.1	**Quality control testing of imported medicinal products**
	2.1.1 Microbiological: sterility
	2.1.2 Microbiological: non-sterility
	2.1.3 Chemical/Physical
	2.1.4 Biological
2.2	**Batch certification of imported medicinal products**
	2.2.1 Sterile Products 2.2.1.1 Aseptically prepared 2.2.1.2 Terminally sterilised
	2.2.2 Non-sterile products
	2.2.3 Biological medicinal products 2.2.3.1 Blood products 2.2.3.2 Immunological products 2.2.3.3 Cell therapy products 2.2.3.4 Gene therapy products 2.2.3.5 Biotechnology products 2.2.3.6 Human or animal extracted products 2.2.3.7 Tissue engineered products 2.2.3.8 Other <free text >
2.3	**Other importation activities**
	2.3.1 Site of physical importation
	2.3.2 Importation of intermediate which undergoes further processing
	2.3.3 Biological active substance
	2.3.4 Other <free text>

Any restrictions or clarifying remarks related to the scope of this notification*:

• **MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES** Active Substance(s):	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps : <free text> (e.g. crystallisation)
	3.1.4 Other <free text>
3.2	**Extraction of Active Substance from Natural Sources**
	3.2.1 Extraction of substance from plant source
	3.2.2 Extraction of substance from animal source
	3.2.3 Extraction of substance from human source
	3.2.4 Extraction of substance from mineral source
	3.2.5 Modification of extracted substance <specify source 1,2,3,4>
	3.2.6 Purification of extracted substance <specify source 1,2,3,4>
	3.2.7 Other <free text>
3.3	**Manufacture of Active Substance using Biological Processes**
	3.3.1 Fermentation
	3.3.2 Cell Culture <specify cell type> (e.g. mammalian / bacterial)
	3.3.3 Isolation / Purification
	3.3.4 Modification
	3.3.5 Other <free text>
3.4	**Manufacture of sterile active substance (sections 3.1, 3.2, 3.3 to be completed as applicable)**
	3.4.1 Aseptically prepared
	3.4.2 Terminally sterilised
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps < specify > (e.g. drying, milling / micronisation, sieving)
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
	3.5.4 Other <free text> (for operations not described above)
3.6	**Quality control testing**
	3.6.1 Physical / Chemical testing

	3.6.2 Microbiological testing (excluding sterility testing)
	3.6.3 Microbiological testing (including sterility testing)
	3.6.4 Biological testing

Part 3

1. Nature of non-compliance (check all relevant boxes)	
☐Analytical validation	☐Housekeeping - cleanliness, tidiness
☐Batch release procedures	☐In-process controls - control and monitoring of production operations
☐Calibration of measuring and test equipment	☐Intermediate and bulk product testing
☐Calibration of reference materials and reagents	☐Investigation of anomalies
☐Cleaning validation	☐Line clearance, segregation and potential for mix-up
☐Complaints and product recall	☐Personnel issues: Duties of key personnel
☐Computerised systems - documentation and control	☐Personnel issues: Hygiene/Clothing
☐Computerised systems - validation	☐Personnel issues: Training
☐Contamination, chemical/physical - potential for	☐Process validation
☐Contamination, microbiological - potential for	☐Production planning and scheduling
☐Design and maintenance of equipment	☐Regulatory issues: Non-compliance with manufacturing authorisation
☐Design and maintenance of premises	☐Regulatory issues: Non-compliance with marketing authorisation
☐Documentation - manufacturing	☐Regulatory issues: Unauthorised activities
☐Documentation - quality system elements/procedures	☐Sampling - procedures and facilities
☐Documentation - specification and testing	☐Self-inspection
☐Environmental control	☐Starting material and packaging component testing
☐Environmental monitoring	☐Status labelling - work in progress, facilities and equipment
☐Equipment qualification	☐Sterility Assurance
☐Finished product testing	☐Supplier and contractor audit and technical agreements
☐Handling and control of packaging components	☐Warehousing and distribution activities

2. Action taken/proposed* by the third country authority or International organisation:
☐ Suspension, variation, revocation* of the manufacturing site approval in full or in part ☐ Withdrawal, of current valid GMP certificate / statement ☐ Suspension, Revocation or Requested Variation* of product registrations ☐ Recall of batches already released ☐ Prohibition of supply ☐ Suspension of clinical trials ☐ Others <free text >
3. Additional comments

Teleconference Date		**Teleconference Time (GMT)**		**Dial in no.**	
EU Products manufactured at site, if known	**Product**	**Dosage Form**	**Reference Member State, National or EMA**		
Human medicinal product(s)					
Veterinary medicinal product(s)					
Investigational medicinal product(s)	**EudraCT nos.**				

Name of the authorised person of the Competent Authority of ..... *[Member State]*

…….
[Name, title, national authority, email, phone & fax numbers in case of enquiries]

…../……/ ..... *[Date]*

(*): delete that which does not apply